Trevi Therapeutics is developing Haduvio, an oral form of nalbuphine, as a treatment for chronic cough in lung disease patients. It last closed at $13.51 on Nov 17, up 1.66% on the day. TRVI last reported earnings on Mon, Nov 9, 2026. Over the past 90 days StreetAlpha recorded 1 whale options trade in TRVI, 100% of them bullish and 0% bearish.
TRVI · as of the Nov 17 close · updated after every close
Moving sideways
The stock is 1% below its 20 day and 3% below its 50 day average. It is 8% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 48). The nearest support is the Pivot at $13.34, and the nearest resistance the 20 day average at $13.64.
Short trendNeutral
Long trendNeutral
MomentumImproving
StretchNormal
VolatilityHigh, 6.2%/day
Key levels
$20.2252 week high+49.7%
$15.91100 day average+17.8%
$14.75Swing high (May 27)+9.2%
$14.55200 day average+7.7%
$13.8950 day average+2.8%
$13.78Pivot R1+2.0%
$13.6420 day average+1.0%
$13.51Last close
$13.34Pivot−1.3%
$13.25Swing low (Jun 3)−1.9%
$13.06Pivot S1−3.3%
$9.8252 week low−27.3%
Indicators
RSI (14)
47.64
Middle of its range
Neutral
MACD
0.03
Above its signal line
Bullish
Stochastic
27.7
Middle of its range
Neutral
ADX (14)
21.8
Weak trend
Williams %R
-73.6
Oversold below −80, overbought above −20
Neutral
CCI (20)
-34.5
Oversold below −100, overbought above 100
Neutral
Rate of change
−2.5%
Change over 10 sessions
Bearish
ATR (14)
$0.84
Typical daily range, 6.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNormal
VolatilityNormal, 12.3%/day
Key levels
$20.2252 week high+49.7%
$15.91100 day average+17.8%
$14.75Swing high (May 27)+9.2%
$14.55200 day average+7.7%
$13.8950 day average+2.8%
$13.78Pivot R1+2.0%
$13.6420 day average+1.0%
$13.51Last close
$13.34Pivot−1.3%
$13.25Swing low (Jun 3)−1.9%
$13.06Pivot S1−3.3%
$9.8252 week low−27.3%
Indicators
RSI (14)
44.53
Middle of its range
Neutral
MACD
-0.40
Below its signal line
Bearish
Stochastic
28.0
Middle of its range
Neutral
ADX (14)
23.0
Weak trend
Williams %R
-76.2
Oversold below −80, overbought above −20
Neutral
CCI (20)
-76.8
Oversold below −100, overbought above 100
Neutral
Rate of change
−15.0%
Change over 10 sessions
Bearish
ATR (14)
$1.66
Typical daily range, 12.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200–
What happened before, for TRVI
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how TRVI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow TRVI usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How TRVI has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TRVI is in one of them and how their past TRVI trades turned out.
Trevi Therapeutics is a biopharmaceutical company based in New Haven, Connecticut, in the United States. It is developing Haduvio, an oral form of nalbuphine, as a treatment for chronic cough. The drug is in clinical trials for patients with idiopathic pulmonary fibrosis, other interstitial lung diseases, and refractory chronic cough. Nalbuphine has been used as an injectable pain medicine for decades, and the company holds worldwide commercial rights to Haduvio.